IL241232B - Cancer treatment agents - Google Patents

Cancer treatment agents

Info

Publication number
IL241232B
IL241232B IL241232A IL24123215A IL241232B IL 241232 B IL241232 B IL 241232B IL 241232 A IL241232 A IL 241232A IL 24123215 A IL24123215 A IL 24123215A IL 241232 B IL241232 B IL 241232B
Authority
IL
Israel
Prior art keywords
cancer
compounds
treatment
Prior art date
Application number
IL241232A
Other languages
English (en)
Hebrew (he)
Other versions
IL241232A0 (en
Original Assignee
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Found filed Critical Univ Tennessee Res Found
Publication of IL241232A0 publication Critical patent/IL241232A0/en
Publication of IL241232B publication Critical patent/IL241232B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL241232A 2013-03-05 2015-09-06 Cancer treatment agents IL241232B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772885P 2013-03-05 2013-03-05
PCT/US2014/020858 WO2014138279A1 (en) 2013-03-05 2014-03-05 Compounds for treatment of cancer

Publications (2)

Publication Number Publication Date
IL241232A0 IL241232A0 (en) 2015-11-30
IL241232B true IL241232B (en) 2021-02-28

Family

ID=51491914

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241232A IL241232B (en) 2013-03-05 2015-09-06 Cancer treatment agents

Country Status (11)

Country Link
US (2) US10022356B2 (enExample)
EP (1) EP2964028A4 (enExample)
JP (2) JP6835472B2 (enExample)
KR (1) KR102246652B1 (enExample)
CN (2) CN105163584B (enExample)
AU (2) AU2014225761B2 (enExample)
CA (1) CA2904338C (enExample)
IL (1) IL241232B (enExample)
MX (2) MX375059B (enExample)
RU (1) RU2708247C2 (enExample)
WO (1) WO2014138279A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
DK2959900T3 (en) * 2008-06-16 2017-06-26 Univ Tennessee Res Found CONNECTION TO TREATMENT OF CANCER
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
EP2964028A4 (en) 2013-03-05 2017-06-07 University of Tennessee Research Foundation Compounds for treatment of cancer
ES2815374T3 (es) 2014-05-06 2021-03-29 Oncternal Therapeutics Inc Compuestos para el tratamiento del cáncer
CN104434924B (zh) * 2014-11-10 2016-09-14 暨南大学 曲美替尼在制备逆转肿瘤多药耐药性药物中的应用
US20190117652A1 (en) * 2014-12-23 2019-04-25 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
WO2016130917A1 (en) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
WO2016197129A1 (en) 2015-06-05 2016-12-08 The Board Of Trustees Of The University Of Illinois Pac-1 combination therapy
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CA2991777A1 (en) * 2015-07-09 2017-01-12 The Jackson Laboratory Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor
CA2995586A1 (en) * 2015-08-06 2017-02-09 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondrial biogenesis for cancer therapy
JP6987084B2 (ja) 2016-03-16 2021-12-22 ディセルナ ファーマシューティカルズ インコーポレイテッド β−カテニン関連疾患又は障害の治療のための組成物及び方法
WO2017200826A1 (en) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP7140103B2 (ja) * 2017-03-10 2022-09-21 コニカミノルタ株式会社 治療有効性の予測方法
JP7291399B2 (ja) * 2017-05-03 2023-06-15 ティン セラピューティクス エルエルシー 難聴の予防および治療のための組成物および方法
AU2018368453B2 (en) 2017-11-17 2024-05-30 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
CN108218855A (zh) * 2018-03-12 2018-06-29 桑文军 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用
AU2019270091A1 (en) * 2018-05-15 2020-12-24 University Of Tennessee Research Foundation Compounds for treatment of pancreatic cancer
EP3793549A4 (en) * 2018-05-15 2022-03-09 University of Tennessee Research Foundation COMPOUNDS FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER
KR20210084442A (ko) 2018-10-05 2021-07-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 포도막 흑색종 치료를 위한 병용 요법
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
JP2023513015A (ja) * 2020-01-31 2023-03-30 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
US20230355581A1 (en) * 2020-07-02 2023-11-09 The Board of Regents of the Unversity of Texas System Methods of treatment for melanoma
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects
WO2022131667A1 (ko) * 2020-12-18 2022-06-23 경희대학교 산학협력단 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
CN115504964A (zh) * 2022-04-12 2022-12-23 海创药业股份有限公司 氘代杂环酮类化合物及其用途
CN117143081B (zh) * 2022-05-24 2025-08-01 赣南医科大学 一种Sabizabulin的制备方法
WO2024036114A2 (en) * 2022-08-08 2024-02-15 The Regents Of The University Of California Combination therapy including cox-2 inhibitor for the treatment of cancer
WO2024186641A1 (en) * 2023-03-03 2024-09-12 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
CN119409641A (zh) * 2024-11-05 2025-02-11 杭州电子科技大学 一种磺酰基衍生物和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
TW311136B (enExample) 1990-11-30 1997-07-21 Otsuka Pharma Co Ltd
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
JP2550915B2 (ja) 1994-06-21 1996-11-06 日本電気株式会社 印刷配線板の表面保護剤および表面保護膜の形成方法
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
WO2003027105A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors
US20040267017A1 (en) 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
WO2003043998A1 (en) 2001-11-15 2003-05-30 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
EP1594847A2 (en) 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
ATE363905T1 (de) 2003-04-17 2007-06-15 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
US20040248957A1 (en) 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
WO2005049591A1 (en) 2003-11-18 2005-06-02 University Of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof
AU2004298486A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
CN1938023A (zh) 2004-03-08 2007-03-28 惠氏公司 离子通道调节剂
EP2298292A3 (en) 2004-06-18 2011-08-10 Agennix USA Inc. Kinase inhibitors for treating cancers
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
DK2395004T3 (en) * 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
US20090239936A1 (en) * 2006-05-15 2009-09-24 Yoshikazu Sugimoto Prophylactic and Therapeutic Agent for Cancer
US7464893B2 (en) * 2006-06-30 2008-12-16 Per Spjut Method of using a cord holder
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
DK2959900T3 (en) 2008-06-16 2017-06-26 Univ Tennessee Res Found CONNECTION TO TREATMENT OF CANCER
ES2745479T3 (es) 2009-10-16 2020-03-02 Novartis Ag Combinación que comprende un inhibidor de MEK y un inhibidor de B-raf
CN102883607B (zh) * 2010-03-01 2015-07-22 Gtx公司 用于治疗癌的化合物
US8426418B2 (en) 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
KR101418229B1 (ko) 2011-03-29 2014-07-09 미쓰비시덴키 가부시키가이샤 서보 제어 장치의 이상 진단 장치 및 이상 진단 시스템
WO2012135759A1 (en) * 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and abiraterone, and methods of use
PL2694510T3 (pl) 2011-04-07 2016-03-31 Bayer Ip Gmbh Imidazopirydazyny jako inhibitory kinazy Akt
EP2964028A4 (en) 2013-03-05 2017-06-07 University of Tennessee Research Foundation Compounds for treatment of cancer

Also Published As

Publication number Publication date
JP2016510748A (ja) 2016-04-11
US10525037B2 (en) 2020-01-07
CN105163584A (zh) 2015-12-16
US10022356B2 (en) 2018-07-17
US20180325872A1 (en) 2018-11-15
EP2964028A4 (en) 2017-06-07
EP2964028A1 (en) 2016-01-13
KR20150123328A (ko) 2015-11-03
RU2015142102A (ru) 2017-04-07
AU2014225761B2 (en) 2018-06-07
KR102246652B1 (ko) 2021-04-29
RU2015142102A3 (enExample) 2018-03-13
CN105163584B (zh) 2019-06-04
JP6835472B2 (ja) 2021-02-24
US20160015688A1 (en) 2016-01-21
JP2019077727A (ja) 2019-05-23
AU2014225761A1 (en) 2015-10-08
MX2020009256A (es) 2020-10-28
CN109568312A (zh) 2019-04-05
RU2708247C2 (ru) 2019-12-05
AU2018226470B2 (en) 2019-11-28
MX375059B (es) 2025-03-06
AU2018226470A1 (en) 2018-09-27
CA2904338A1 (en) 2014-09-12
IL241232A0 (en) 2015-11-30
CA2904338C (en) 2022-07-05
MX2015011713A (es) 2016-05-09
WO2014138279A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
IL241232A0 (en) Cancer treatment agents
EP2968348A4 (en) COMPOUNDS FOR THE TREATMENT OF CANCER
LT3033086T (lt) Kombinuota terapija vėžiui gydyti
IL285077A (en) Compounds for the treatment of cancer
SG11201508223YA (en) Treatment of cancer with dihydropyrazino-pyrazines
ZA201507733B (en) Treatment of cancer with dihydropyrazino-pyrazines
SG11201508878WA (en) Methods of treating cancer
IL242546A0 (en) New compounds for cancer treatment
EP2903644A4 (en) TREATMENT OF CANCER
PL3062790T3 (pl) Połączenia farmaceutyczne do leczenia raka
IL245037B (en) Treatment for pancreatic cancer
GB201217892D0 (en) Treatment of cancer
EP3011013A4 (en) Methods for treatment of ovarian cancer
GB201308466D0 (en) Improved process for treatment of minewater
ZA201507762B (en) Methods of treating cancer
HUE049301T2 (hu) Kurkofenol-vegyület rák kezelésére
GB201403083D0 (en) Treatment of cancer
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
EP3049078A4 (en) Treatment of cancer
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
EP3007712A4 (en) Treatment of cancer
GB201217890D0 (en) Treatment of cancer
AP2015008905A0 (en) Novel compounds for the treatment of cancer
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed